NCT Number: NCT02082028
Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin
To demonstrate the superiority of a chronic care model (SINERGIA model) supported by the Self Monitoring of Blood Glucose with BGStar over usual care in improving glycemic control at 12 months in patients with type 2 diabetes not treated with insulin.
Looking for future studies?
Notify MeKey information
Conditions
Age range
45 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Investigational Site Number 016, Andria (BA), Italy
About this study
The planned study duration is 36 months (9 quarters). The estimated duration of screening/enrollment will be 12 months, followed by the 12-month experimental phase, plus the 12-month follow-up in the observational phase.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Males and females
- Age ≥ 45 years
- Type 2 diabetes
- First access at the diabetes clinic
- Any diabetes duration
- HbA1c >7.0 and ≤ 9.0%
- Already treated with any oral antidiabetic agent (OAD) or requiring the initiation of therapy with OAD
- Patients not using SMBG or using SMBG with a frequency ≤1 test/week
- Written informed consent
Exclusion criteria
Treatment with insulin or need to start insulin regimens or continuous sub-cutaneous insulin infusion at the first access; Refusal or inability to give informed consent to participate in the study;
Conditions / situations such as:
- Patients with short life expectancy;
- Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint according to physician's judgment;
- Requirement for concomitant treatment that could bias primary evaluation (i.e. corticosteroid treatment);
- Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other study site staff or relative of study site staff thus considered directly involved in the conduct of the study;
- Current addition/abuse of alcohol or drugs;
- Patients with any mental condition rendering them unable to understand the nature, scope, and possible consequences of the study;
- Pregnant or breast-feeding women;
- Patients living too far from investigational center or other conditions reducing the adherence to the protocol; Subjects unlikely or unable to comply with the Protocol requirements (e.g. illiterate, uncooperative, unable to return for follow-up visit, unable to use BGStar unlikely to complete the study)
Treatment and study plan
Glucose Meter
DevicePrimary outcomes
-
Change in HbA1c levels from baseline
Time frame: baseline to 12 months
Secondary outcomes
-
Percentage of participants with HbA1c ≤7.0%
Time frame: at 12 months and 24 months
-
Variation in body weight from baseline
Time frame: at 12 months and 24 months
-
Variation in waist circumference from baseline
Time frame: at 12 months and 24 months
-
Variation in blood pressure from baseline
Time frame: at 12 months and 24 months
-
Variation in lipid profile from baseline
Time frame: at 12 months and 24 months
-
Quality of life: SF12 (Health Survey) questionnaire
Time frame: at 12 months and 24 months
-
ADDQOL (Audit of Diabetes-Dependent Quality of Life)
Time frame: at 12 months and 24 months
-
DTSQ (Diabetes Treatment Satisfaction Questionnaire)
Time frame: at 12 months and 24 months
-
ABIM-14 (American Board of Internal Medicine satisfaction questionnaire)
Time frame: at 12 months and 24 months
-
PDM (Patient involvement in the Decision Making process) questionnaire
Time frame: at 12 months and 24 months
-
PHCO (Patient Health Care Orientation) questionnaire
Time frame: at 12 months and 24 months
-
Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS)
Time frame: at 12 months and 24 months
Sponsors and collaborators
Lead sponsor
Sanofi
Industry
Registry information
Official study title
Randomized Clinical Trial on the Efficacy of Self-Monitoring Blood Glucose in the Context of a Chronic Care Model for Type 2 Diabetes Patients Treated With Oral Agents Only
Acronym: SELF CARE
Important dates
- Study start
- 2012
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Mar 7, 2014
- Registry last updated
- May 3, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Diabetes Prevention Program Outcomes Study
NCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsA Sugar-Sweetened Beverage Reduction Intervention for Native American Men
NCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsLinks Between Inflammation and Cardiometabolic Diseases
NCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsCold Spray for Insulin-Injection Pain in the Emergency Department
NCT07728162
Diabetes Mellitus, Disease Attributes
Bolu, Turkey (Türkiye)
View Trial Details